Saluda Medical, Inc. (ASX:SLD)

Saluda Medical Income Statement

Financials in millions USD. Fiscal year is July - June.

Fiscal Year	TTM	FY 2025	FY 2024	FY 2023
Period Ending	Dec 31, 2025	Jun 30, 2025	Jun 30, 2024	Jun 30, 2023
Revenue	76.07	70.36	51.68	22.23
Revenue Growth (YoY)	242.12%	36.13%	132.45%	-
Cost of Revenue	39.76	37.6	28.57	18.2
Gross Profit	36.31	32.76	23.11	4.04
Selling, General & Admin	130.64	115.35	93.05	68.15
Research & Development	35.15	35.46	29.2	28.11
Operating Expenses	165.77	150.81	122.25	96.26
Operating Income	-129.46	-118.05	-99.14	-92.22
Interest Expense	-32.28	-27.24	-5	-4.67
Interest & Investment Income	1.92	2.01	5.47	3.21
Currency Exchange Gain (Loss)	1.14	1.65	0.11	1.43
Other Non Operating Income (Expenses)	-1.47	-7.15	1	0.7
Pretax Income	-161.85	-148.77	-97.55	-91.55
Income Tax Expense	0.75	0.53	0.27	0.61
Net Income	-162.61	-149.3	-97.83	-92.16
Net Income to Common	-252.65	-149.3	-97.83	-92.16
Shares Outstanding (Basic)	39	3	3	3
Shares Outstanding (Diluted)	39	3	3	3
Shares Change (YoY)	1086.55%	0.13%	0.06%	-
EPS (Basic)	-6.56	-45.92	-30.13	-28.40
EPS (Diluted)	-6.56	-45.92	-30.13	-28.40
Free Cash Flow	-122.08	-119.51	-94.4	-88.03
Free Cash Flow Per Share	-3.17	-36.75	-29.07	-27.13
Gross Margin	47.73%	46.56%	44.72%	18.17%
Operating Margin	-170.20%	-167.79%	-191.82%	-414.78%
Profit Margin	-332.14%	-212.21%	-189.29%	-414.52%
Free Cash Flow Margin	-160.49%	-169.87%	-182.66%	-395.93%
EBITDA	-127.79	-116.4	-97.25	-90.94
EBITDA Margin	-168.00%	-165.45%	-188.17%	-
D&A For EBITDA	1.67	1.65	1.89	1.29
EBIT	-129.46	-118.05	-99.14	-92.22
EBIT Margin	-170.20%	-167.79%	-191.82%	-

Source: S&P Global Market Intelligence. Standard template. Financial Sources.